See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $20.0B | 11.1x | -84.4x | |
| $14.1B | 3.3x | 12.2x | |
| $11.9B | 4.1x | 32.4x | |
| $5.7B | 7.2x | -23.4x | |
| $2.9B | 5.2x | 104.2x | |
| $2.1B | 2.4x | 13.8x | |
| $2.1B | 4.4x | 20.9x | |
| $1.8B | 5.0x | -12.2x | |
| $1.7B | 5.2x | 76.9x | |
| $1.0B | 1.6x | 17.0x | |
| $841M | 1.4x | -5.4x | |
| $819M | 6.1x | -0.8x | |
| $701M | 4.5x | -3.0x | |
| $697M | 2.0x | 23.8x | |
| $644M | 2.1x | 12.3x | |
| $445M | 0.5x | 13.1x | |
| $404M | 54.3x | -4.4x | |
| $393M | 4.5x | n/a | |
| $336M | 6.6x | -5.4x | |
| $328M | 2.2x | -1.6x | |
| $313M | 3.7x | -4.5x | |
| $305M | 1.0x | -32.2x | |
| $259M | n/a | n/a | |
| $253M | n/a | n/a | |
| $242M | 0.8x | 4.9x | |
| $241M | 100.9x | -15.2x | |
| $233M | 54.3x | -43.9x | |
| $200M | 10.8x | n/a | |
| $199M | 66.9x | n/a | |
| $170M | 2.5x | -4.3x | |
| $157M | n/a | n/a | |
| $144M | 22.5x | -0.8x | |
| $94.1M | 1.7x | -1.3x | |
| $91.5M | n/a | -0.6x | |
| $87.5M | 18.6x | -0.5x | |
| $76.3M | 30.5x | n/a | |
| $31.7M | 0.7x | 4.9x | |
| $25.7M | 0.5x | -0.4x | |
| $18.1M | n/a | n/a | |
| $12.3M | 17.1x | -0.1x | |
| $10.1M | n/a | n/a | |
| $9.7M | 0.3x | -0.2x | |
| $2.6M | 1.6x | -0.0x | |
| -$2.0M | -0.0x | 0.1x | |
| -$2.7M | n/a | n/a | |
| -$11.1M | n/a | 0.1x | |
| -$12.5M | -0.2x | 0.1x | |
| -$14.7M | -22.7x | 0.2x | |
| -$17.6M | n/a | 0.2x | |
| -$32.9M | n/a | n/a | |
| -$41.9M | n/a | 0.5x | |
| -$43.7M | -2.4x | n/a | |
| -$64.3M | -2.5x | 0.3x | |
| -$83.5M | -2.8x | 0.3x | |
| -$90.1M | -4.0x | n/a | |
| -$109M | -11.0x | 0.7x | |
| -$143M | -3.1x | 1.6x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine